HB18-1009 - Diabetes Drug Pricing Transparency Act 2018

Concerning transparency in diabetes prescription drugs pricing.

The bill creates the 'Diabetes Drug Pricing Transparency Act of 2018'. The state board of health is responsible for implementing the act. Drug manufacturers and pharmacy benefit managers must submit annual reports to the state board regarding drugs used to treat diabetes that are subject to price increases of certain percentages. The state board analyzes the submitted information and publishes a report. The state board may impose penalties on drug manufacturers or pharmacy benefit managers who do not comply with reporting requirements. Nonprofit organizations advocating for patients with diabetes or funding diabetes medical research that receive contributions from certain diabetes drug manufacturers must annually report those contributions.
(Note: This summary applies to this bill as introduced.)

Latest update: January 10, 2018
01/10/2018 - Introduced In House - Assigned to Health, Insurance, & Environment